OTC Obesity - France

Date: April 22, 2010
Pages: 49
Price:
US$ 990.00
Publisher: Euromonitor International Ltd
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O08C2E5D65DEN
Leaflet:

Download PDF Leaflet

The main story in OTC obesity was the entrance of Alli by GlaxoSmithKline in 2009. According to trade press, this type of event only occurs every 10 years in the pharmaceuticals market, the last time being the launch of Viagra in Rx form. The launch of Alli triggered many articles in the media, heated reaction, criticism from experts and varied consumer opinion on Internet blogs and messageboards, which ultimately resulted in free advertising for the GlaxoSmithKline brand.

Euromonitor International's OTC Obesity Products in France report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.

Product coverage:

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
  • Get a detailed picture of the Consumer Health industry;
  • Pinpoint growth sectors and identify factors driving change;
  • Understand the competitive environment, the market’s major players and leading brands;
  • Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town and Santiago and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.
Executive Summary
Consumer Health Lacks Dynamism
Launch of OTC Obesity Causes Controversy in Consumer Health
Consumer Health Characterised by Fragmented Competitive Environment
Chemists/pharmacies Continue To Dominate Retail Channels
Lack of Growth Will Cause Stagnation
Key Trends and Developments
Self-service: Old Habits Die Hard As Consumers Prefer Advice From Chemists/pharmacists
Consumer Health Battles Against 'alicaments', Highly Functional Foods
Stressful, Busy Lifestyles Influence Natural Choices
Fat Fighting - OTC Obesity Category Launched With New Product Alli
Consumer Health Is Fragmented But Targeted
Market Indicators
  Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009
  Table 2 Life Expectancy at Birth 2004-2009
Market Data
  Table 3 Sales of Consumer Health by Sector: Value 2004-2009
  Table 4 Sales of Consumer Health by Sector: % Value Growth 2004-2009
  Table 5 Consumer Health Company Shares by Value 2005-2009
  Table 6 Consumer Health Brand Shares by Value 2006-2009
  Table 7 Penetration of Private Label by Sector 2004-2009
  Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009
  Table 9 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009
  Table 10 Forecast Sales of Consumer Health by Sector: Value 2009-2014
  Table 11 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014
Appendix
OTC Registration and Classification
Advertising
Packaging and Labelling
Distribution
Vitamins and Dietary Supplements Registration and Classification
EU Legislation
Self-medication/self-care and Preventive Medicine
Generics
Switches
  Summary 1 OTC Healthcare Switches 2007-2009
Definitions
Sector and Subsector Definitions
  Summary 2 Research Sources
Arkopharma Sa, Laboratoires Pharmaceutiques
Strategic Direction
Key Facts
  Summary 3 Laboratoires Pharmaceutiques Arkopharma SA: Key Facts
  Summary 4 Laboratoires Pharmaceutiques Arkopharma SA: Operational Indicators
Company Background
Competitive Positioning
  Summary 5 Laboratoires Pharmaceutiques Arkopharma SA: Competitive Position 2009
Beaufour-ipsen SA
Strategic Direction
Key Facts
  Summary 6 Beaufour-Ipsen SA: Key Facts
  Summary 7 Beaufour-Ipsen SA: Operational Indicators
Company Background
Production
  Summary 8 Beaufour-Ipsen SA: Production Statistics
Competitive Positioning
  Summary 9 Beaufour-Ipsen SA: Competitive Position 2009
Cooper SA
Strategic Direction
Key Facts
  Summary 10 Cooper SA: Key Facts
  Summary 11 Cooper SA: Operational Indicators
Company Background
Production
  Summary 12 Cooper SA: Production Statistics
Competitive Positioning
  Summary 13 Cooper SA: Competitive Position 2009
GlaxoSmithKline Santé Grand Public Sas
Strategic Direction
Key Facts
  Summary 14 GlaxoSmithKline Santé Grand Public SAS: Key Facts
  Summary 15 GlaxoSmithKline Santé Grand Public SAS: Operational Indicators
Company Background
Production
  Summary 16 GlaxoSmithKline France: Production Statistics
Competitive Positioning
  Summary 17 GlaxoSmithKline Santé Grand Public SAS: Competitive Position 2009
Juva Santé, Groupe
Strategic Direction
Key Facts
  Summary 18 Laboratoires Juva Santé: Key Facts
Company Background
Production
  Summary 20 Laboratoires Juva Santé: Production Statistics
Competitive Positioning
  Summary 21 Laboratoires Juva Santé: Competitive Position 2009
Laboratoires Mcneil
Strategic Direction
Key Facts
  Summary 22 Laboratoires McNeil: Key Facts
  Summary 23 Laboratoires McNeil: Operational Indicators
Company Background
Competitive Positioning
  Summary 24 Laboratoires McNeil: Competitive Position 2009
Pierre Fabre Sa, Laboratoires
Strategic Direction
Key Facts
  Summary 25 Laboratoires Pierre Fabre SA: Key Facts
  Summary 26 Laboratoires Pierre Fabre SA: Operational Indicators
Company Background
Production
  Summary 27 Laboratoires Pierre Fabre SA: Production Statistics
Competitive Positioning
  Summary 28 Laboratoires Pierre Fabre SA: Competitive Position 2009
Théraplix SA
Strategic Direction
Key Facts
  Summary 29 Théraplix SA: Key Facts
Company Background
Competitive Positioning
  Summary 30 Théraplix SA: Competitive Position 2009
Upsa, Laboratoires
Strategic Direction
Key Facts
  Summary 31 Laboratoires UPSA: Key Facts
  Summary 32 Laboratoires UPSA: Operational Indicators
Company Background
Production
  Summary 33 Laboratoires UPSA: Production Statistics
Competitive Positioning
  Summary 34 Laboratoires UPSA: Competitive Position 2009
Urgo, Laboratoires
Strategic Direction
Key Facts
  Summary 35 Laboratoires Urgo: Key Facts
  Summary 36 Laboratoires Urgo: Operational Indicators
Company Background
Production
Competitive Positioning
  Summary 37 Laboratoires Urgo: Competitive Position 2009
Trends
Category Data
  Table 12 Sales of OTC Obesity: Value 2009
  Table 13 OTC Obesity Company Shares by Value 2005-2009
  Table 14 OTC Obesity Brand Shares by Value 2006-2009
  Table 15 Forecast Sales of OTC Obesity: Value 2009-2014
  Table 16 Forecast Sales of OTC Obesity: % Value Growth 2009-2014
Skip to top


OTC Obesity - Australia US$ 990.00 Jun, 2010 · 33 pages
OTC Obesity - Austria US$ 990.00 Apr, 2010 · 31 pages
OTC Obesity - Denmark US$ 990.00 Apr, 2010 · 29 pages
OTC Obesity - Greece US$ 990.00 Mar, 2010 · 33 pages
OTC Obesity - Netherlands US$ 990.00 Jun, 2010 · 32 pages

Ask Your Question

OTC Obesity - France
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: